

Greater Manchester Strategic Clinical Network and Takeda Pharmaceuticals Limited.

Joint Working Project Executive Summary

The Greater Manchester Strategic Clinical Network (GM SCN) and Takeda Pharmaceuticals Limited, were engaged in Joint Working to help to develop a standards-led approach to delivering ADHD services for children and young people across Greater Manchester (GM). The parties agreed that the Project was undertaken in accordance with the principles and guidance relating to joint working between the NHS and the pharmaceutical industry. The primary objective of the Project was to bring benefits to patients and improve patient outcomes through high quality, cost effective treatment and management aligned to agreed standards. The financial commitments of both parties were similar and significant and, in total, fell in the range of £20,000 – £31,000. The Project has brought benefits to the patient, Greater Manchester Strategic Clinical Network and Takeda.

The Project commenced in January 2018 and completed in January 2019 and has brought benefits to patients, the GM SCN, and Takeda. The results will be available within the NHS trust.

The objective of the Joint Working project was to improve the standards of ADHD services across the boroughs of Greater Manchester.

It was designed to support:

- Patient outcomes
- Reduced waiting times
- More effective assessment and treatment
- Training for relevant medical and non-medical practitioners, especially on the use of appropriate objective tests for ADHD including rating scales and diagnostic tools.

It is anticipated that a report on the outcomes from this joint working will be published during 2021.

For further information please contact:

Alison Carroll, Service Development , Takeda, alison.carroll@takeda.com : 07795236134

GM SCN Katherine McGuirk, Quality Improvement Manager, CYP Mental Health & Wellbeing - ADHD
Greater Manchester Health and Social Care Partnership, 4th Floor, 3 Piccadilly Place, Manchester.
M1 3BN